modelCyclophosphamide_1
Extends from Pharmacolibrary.Drugs.ATC.L.L01AA01_1.
Information
| name: | Cyclophosphamide_1 | |
| ATC code: | L01AA01_1 | route: | oral |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 34 | L |
| clearance: | 3.6 | L/h |
| other parameters in model implementation | ||
Cyclophosphamide is an alkylating agent used in cancer chemotherapy and for immune modulation in some autoimmune diseases. It is approved and clinically in use.
Pharmacokinetics
Pharmacokinetics of cyclophosphamide in healthy adult volunteers after oral administration.
References
Veluvolu, S, et al., & Wittenburg, L (2023). Fractionated oral dosing and its effect on cyclophosphamide pharmacokinetics in dogs with high-grade multicentric lymphoma. Veterinary and comparative oncology 21(1) 20–27. DOI:10.1111/vco.12856 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36057542
Hadjibabaie, M, et al., & Sadrai, S (2011). Population pharmacokinetics of oral high-dose busulfan in adult patients undergoing hematopoietic stem cell transplantation. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 19(3) 216–223. PUBMED:https://pubmed.ncbi.nlm.nih.gov/22615660
Tran, HT, et al., & Chan, KW (2000). Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone marrow transplantation 26(5) 463–470. DOI:10.1038/sj.bmt.1702561 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11019834
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)